Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

C2 Pharma boosts digoxin business

by Michael McCoy
March 22, 2019 | A version of this story appeared in Volume 97, Issue 12

 

A photo of the foxglove plant.
Credit: Shutterstock
Digoxin is extracted from the leaves of Digitalis lanata, also called foxglove.

C2 Pharma, a supplier of niche active pharmaceutical ingredients (APIs), has acquired the digoxin API business of the Polish firm Nobilus Ent. C2 says the purchase complements production of digoxin that the Indian firm Laurus Labs conducts on its behalf. Digoxin is a plant extract used to treat heart conditions. C2 says it is responding to supply inconsistency due to high impurity levels and an unreliable supply chain.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.